Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibrx BiosciencesINBX +4.19%10 3-1 Month Momentum % is -0.53% as of Sep. 09, 2026. GuruFocus rates INBX with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,386 Biotechnology companies, Inhibrx Biosciences ranks worse than 52.45% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-09), Inhibrx Biosciences's 3-1 Month Momentum % is -0.53%.
The industry rank for Inhibrx Biosciences's 3-1 Month Momentum % or its related term are showing as below:
INBX's 3-1 Month Momentum % is ranked worse than 52.45% of 1386
companies
in the Biotechnology industry
Industry Median: 1.085
vs INBX: -0.53
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Inhibrx Biosciences 3-1 Month Momentum % Related Terms
INBX vs SEPN, NTLA, RXRX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Inhibrx Biosciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibrx Biosciences 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Inhibrx Biosciences's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibrx Biosciences (INBX) has a 3-1 Month Momentum % of -0.53% as of Sep. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Inhibrx Biosciences and its competitors. According to the industry distribution chart, Inhibrx Biosciences ranks #727 out of 1386 companies in the Biotechnology industry, placing it in the top 52.5%.
Is Inhibrx Biosciences' 3-1 Month Momentum % too high?
Inhibrx Biosciences' current 3-1 Month Momentum % is -0.53%. Based on the distribution chart, Inhibrx Biosciences ranks #727 out of 1386 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Inhibrx Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Inhibrx Biosciences' 3-1 Month Momentum % compare to SEPN and NTLA?
According to the Biotechnology industry distribution chart, Inhibrx Biosciences ranks #727 out of 1386 companies for 3-1 Month Momentum %. This places Inhibrx Biosciences in the lower half of its industry. The industry median 3-1 Month Momentum % is 1.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.09, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Inhibrx Biosciences and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibrx Biosciences's current 3-1 Month Momentum % is -0.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibrx Biosciences stock overvalued right now?
Inhibrx Biosciences (INBX) has a current 3-1 Month Momentum % of -0.53%. The current 3-1 Month Momentum % is -0.53%. Inhibrx Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Inhibrx Biosciences (INBX), the current 3-1 Month Momentum % is -0.53% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
10GF Score
Get the complete analysis for INBX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBX has been successfully added to your 
